rxstat › Shortages › Ranibizumab
Ranibizumab shortage status
Partial shortage
Reports by product
What's happening
Ranibizumab is currently affected by an active shortage report filed with Health Canada by SAMSUNG BIOEPIS CO., LTD.
The reported cause is: other (please describe in comments). Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Ranibizumab is classified under “OCULAR VASCULAR DISORDER AGENTS” (ATC S01LA).
Recent changes
- No changes recorded yet.
Common questions
When will Ranibizumab be back in stock in Canada?
The latest manufacturer estimate is Jun 30, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Ranibizumab in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Related drugs (ocular vascular disorder agents)
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.